AIDX Stock Summary and Trading Ideas (20/20 Biolabs | NASDAQ:AIDX)

20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.

What symbol and exchange does 20/20 Biolabs shares trade?

20/20 Biolabs trades on the NASDAQ stock market under the symbol AIDX.

What is 20/20 Biolabs stock price doing today?

As of June 12, 2026, AIDX stock price climbed to $0.96 with 126,253 million shares trading.

What is 20/20 Biolabs's Beta?

AIDX has a beta of 3.94, meaning it tends to be more sensitive to market movements. AIDX has a correlation of 0.06 to the broad based SPY ETF.

How much is 20/20 Biolabs worth?

AIDX has a market cap of $10.22 million. This is considered a Sub-Micro Cap stock.

How much money does 20/20 Biolabs make?

Last quarter 20/20 Biolabs reported $353,375 in Revenue and -$.28 earnings per share. This fell short of revenue expectation by $-425,625 and missed earnings estimates by -$.18.

What are the support and resistance levels for 20/20 Biolabs (AIDX)?

AIDX support price is $.78 and resistance is $.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AIDX shares will trade within this expected range on the day.